Norwich Union has blamed IFAs over its controversial use of three genetic tests when underwriting life insurance.
Before the Parliamentary science and technology committee last week, chief actuary Mike Urmston said as NU is in the IFA sector, it must have access to all available information.
The three tests are for Huntington's disease, Alzheimer's disease and ovary and breast cancer. Only Huntington's is officially approved by the Government's genetics committee although all three are approved by the ABI.
Urmston says NU needs to use the tests because its average IFA policy is much bigger than for companies operating in the direct market and it says it only applies the test results on policies over £100,000.
But CIS hit back, saying, at this point, the impact on premiums is negligible so it is irrelevant what size the policies are.
l Comment, p35